A Search for Optimal Criteria in Initiating Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection Focusing on CD4 Count and HIV RNA

References

• Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV-disease. Ann Intern Med 2001; 135: 17–26.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994–98: the Euro-SIDA study. Lancet 2000; 356: 291–6.
   PubMed Web of Science ®Google Scholar
• Moore R, Keruly J, Chaisson R. Differences in anion gap with different nucleoside TRI combinations. Abstract 55, Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 30 January-2 February 2000.
   Google Scholar
• Bartlett J. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. Abstract 19, Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 4–8 February 2001. (Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/19.htm).
   Google Scholar
• US Department of Health and Human Services and Henry J. Kaiser Family Foundation Panel on Clinical Practices for Treatment of HIV-infection. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. (Available at: http://www.hivatis.org).
   Google Scholar
• Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41(RR-17): 1–19.
   Google Scholar
• O’Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4 + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426–31.
   Google Scholar
• Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–54.
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Keruly JC, Moore RD. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy (Letter). JAMA 2000; 284: 3128–9.
   Google Scholar
• Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560–7.
   PubMed Web of Science ®Google Scholar
• Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the years after initiation of potent antiretroviral therapy. J AIDS 2001; 27: 168–75.
   PubMed Web of Science ®Google Scholar
• Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130: 570–7.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863–8.
   PubMed Web of Science ®Google Scholar
• Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, et al. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000; 14: 2129–36.
   PubMed Web of Science ®Google Scholar
• Balslev U, Monforte A, Stergiou G, Antunes F, Mulchahy F, Pehrson PO, et al. Influence of age on rates of new AIDS-defining diseases and survival ickborne encin 6546 AIDS patients. Scand J Infect Dis 1997; 29: 337–43.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Yip B, Chan KJ, Wood E, Craib KJP, O’Shaughnessy MV, Montaner JSG. Rates of disease progression by baseline CD4 cell count and viral load after initiating tripledrug therapy. JAMA 2001; 286: 2568–77.
   Google Scholar